Ann: MSB Enters Into $75 Million Non-Dilutive Credit Facility, page-45

@Warrigals

I don't doubt there are strings attached, but what debt facility doesn't?

Its all academic if Mesoblast are able to get the product to market and distribute it to the 30 clinics in the US who treat pediatric aGVHD (we already have relationships with 15 of these).

If pediatric aGVHD can't generate revenues being the best in care and no alternative products available in the US... then most of us here won't be shareholders for long.

The great thing now is that I can say with absolute confidence we will at least find out, that is something we couldn't say a few months ago.

In terms of revenue guidance, I've done a back of the envelope on another thread based on actual cash receipts from Temcell and how that extrapolates to the global and US/EU market. The information is out there, just need to take 10 minutes to put it together.